Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Risks and Benefits of Bisphosphonate Therapies.

Reyes C, Hitz M, Prieto-Alhambra D, Abrahamsen B.

J Cell Biochem. 2016 Jan;117(1):20-8. doi: 10.1002/jcb.25266. Review.

PMID:
26096687
2.

Benefits and risks of bisphosphonate therapy for osteoporosis.

Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT.

J Clin Endocrinol Metab. 2012 Jul;97(7):2272-82. doi: 10.1210/jc.2012-1027. Review.

PMID:
22523337
3.

Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Lewiecki EM.

Drugs. 2011 Apr 16;71(6):791-814. doi: 10.2165/11585470-000000000-00000. Review.

PMID:
21504254
4.

Long-term use of bisphosphonates in osteoporosis.

Watts NB, Diab DL.

J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. doi: 10.1210/jc.2009-1947. Review.

PMID:
20173017
5.

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM.

Am J Med. 2013 Jan;126(1):13-20. doi: 10.1016/j.amjmed.2012.06.023. Review.

PMID:
23177553
6.

Safety of bisphosphonates.

Orozco C, Maalouf NM.

Rheum Dis Clin North Am. 2012 Nov;38(4):681-705. doi: 10.1016/j.rdc.2012.09.001. Review.

PMID:
23137577
7.

Long term bisphosphonate use in osteoporotic patients; a step forward, two steps back.

Salari P, Abdollahi M.

J Pharm Pharm Sci. 2012;15(2):305-17. Review.

8.

Bisphosphonates in the treatment of osteoporosis.

Diab DL, Watts NB.

Endocrinol Metab Clin North Am. 2012 Sep;41(3):487-506. doi: 10.1016/j.ecl.2012.04.007. Review.

PMID:
22877426
9.

Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies.

Reid IR.

Skeletal Radiol. 2011 Sep;40(9):1191-6. doi: 10.1007/s00256-011-1164-9. Review.

PMID:
21847749
10.

Bisphosphonates for steroid-induced osteoporosis.

Allen CS, Yeung JH, Vandermeer B, Homik J.

Cochrane Database Syst Rev. 2016 Oct 5;10:CD001347. Review.

PMID:
27706804
11.

Bisphosphonates in multiple myeloma: a network meta-analysis.

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B.

Cochrane Database Syst Rev. 2012 May 16;(5):CD003188. doi: 10.1002/14651858.CD003188.pub3. Review.

PMID:
22592688
12.

Bisphosphonates for the prevention and treatment of osteoporosis.

Maraka S, Kennel KA.

BMJ. 2015 Sep 2;351:h3783. doi: 10.1136/bmj.h3783. Review.

13.

Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.

Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, Goltzman D, Hanley DA, Hodsman A, Josse R, Jovaisas A, Juby A, Kaiser S, Karaplis A, Kendler D, Khan A, Ngui D, Olszynski W, Ste-Marie LG, Adachi J.

Can Fam Physician. 2014 Apr;60(4):324-33. Review.

14.

Bisphosphonates for osteoporosis in people with cystic fibrosis.

Conwell LS, Chang AB.

Cochrane Database Syst Rev. 2014 Mar 14;(3):CD002010. doi: 10.1002/14651858.CD002010.pub4. Review.

PMID:
24627308
15.

Bisphosphonates for osteoporosis in people with cystic fibrosis.

Conwell LS, Chang AB.

Cochrane Database Syst Rev. 2012 Apr 18;(4):CD002010. doi: 10.1002/14651858.CD002010.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;(3):CD002010.

PMID:
22513903
16.

Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?

McClung M.

Clin Obstet Gynecol. 2013 Dec;56(4):743-8. doi: 10.1097/GRF.0b013e3182a98295. Review.

PMID:
24177063
17.

Bisphosphonate therapy for osteogenesis imperfecta.

Dwan K, Phillipi CA, Steiner RD, Basel D.

Cochrane Database Syst Rev. 2016 Oct 19;10:CD005088. Review.

PMID:
27760454
18.

The bisphosphonates: risks and benefits of long term use.

Hermann AP, Abrahamsen B.

Curr Opin Pharmacol. 2013 Jun;13(3):435-9. doi: 10.1016/j.coph.2013.02.002. Review.

PMID:
23434194
19.

The use of bisphosphonates in cancer patients.

Wu S, Dahut WL, Gulley JL.

Acta Oncol. 2007;46(5):581-91. Review.

PMID:
17562434
20.

Long-term risks of bisphosphonate therapy.

Watts NB.

Arq Bras Endocrinol Metabol. 2014 Jul;58(5):523-9. Review.

Items per page

Supplemental Content

Support Center